Literature DB >> 16841548

Meaning of DNA detection during the follow-up of HIV-1 infected patients: a brief review.

Maria Carla Re1, Francesca Vitone, Isabella Bon, Pasqua Schiavone, Davide Gibellini.   

Abstract

A growing body of evidence indicates that proviral DNA load quantitation is an important parameter in establishing the dynamics of HIV infection. Proviral DNA load can be determined during the follow-up of infected individuals to evaluate reservoir status in addition to viral replication. Hence, the study of viral reservoirs, represented by HIV-1 latently infected cells, including resting memory CD4+ T cells, monocytes and macrophages, by which HIV-1 can be reactivated, opens new perspectives in the assessment and the comprehension of HIV-1 infection. However, the identification of viral reservoirs, that can store both wild and drug resistance viruses, is one of the most important steps in developing treatment strategies because it is now clear that viral reservoirs not only prevent sterilizing immunity but also represent a major obstacle to curing the infection with the potent antiretroviral drugs currently in use. Even if only careful evaluation of virological and immunological markers is necessary to fully characterize the course of HIV-1 infection and to provide a more complete laboratory-based assessment of disease progression, the availability of a new standardized assay such as DNA proviral load will be important to assess the true extent of virological suppression in treated patients and to verify the efficacy of new immune-based therapies aimed at purging HIV-1 DNA reservoirs. Several studies demonstrate, in fact, that HIV-1 cellular DNA load may be an indicator of spread of infection whereas the plasma RNA load is indicates active infection. This article will review the importance of monitoring HIV-1 proviral load DNA during the follow-up of HIV-1 infected subjects, suggesting that additional information complementing HIV RNA load could provide crucial information to monitor viral replication and the effectiveness of HAART therapy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16841548

Source DB:  PubMed          Journal:  New Microbiol        ISSN: 1121-7138            Impact factor:   2.479


  9 in total

1.  Human Papillomavirus at Multiple Sites Associated with Anal Squamous Intraepithelial Lesions in HIV-Seropositive Individuals.

Authors:  Eleanore Chuang; Eunjung Lim; Cris Milne; Xuemei Zhu; Melissa Agsalda; Jeffrey Killeen; F DeWolfe Miller; Brenda Y Hernandez; Bruce Shiramizu
Journal:  Ann Clin Cytol Pathol       Date:  2016-07-12

2.  Regional cortical thinning associated with detectable levels of HIV DNA.

Authors:  Kalpana J Kallianpur; Gregory R Kirk; Napapon Sailasuta; Victor Valcour; Bruce Shiramizu; Beau K Nakamoto; Cecilia Shikuma
Journal:  Cereb Cortex       Date:  2011-10-19       Impact factor: 5.357

3.  Presence of high-risk human papillomavirus genotype and human immunodeficiency virus DNA in anal high-grade and low-grade squamous intraepithelial lesions.

Authors:  Bruce Shiramizu; Chin-Yuan Liang; Melissa Agsalda-Garcia; Ian Nagata; Cris Milne; Xuemei Zhu; Jeffrey Killeen; J Michael Berry; Marc T Goodman
Journal:  AIDS Res Hum Retroviruses       Date:  2012-08-27       Impact factor: 2.205

Review 4.  HIV DNA in circulating monocytes as a mechanism to dementia and other HIV complications.

Authors:  Victor G Valcour; Bruce T Shiramizu; Cecilia M Shikuma
Journal:  J Leukoc Biol       Date:  2010-02-03       Impact factor: 4.962

5.  Viral load and CD4+ T-cell dynamics in primary HIV-1 subtype C infection.

Authors:  Vladimir Novitsky; Elias Woldegabriel; Lemme Kebaabetswe; Raabya Rossenkhan; Busisiwe Mlotshwa; Caitlin Bonney; Mariel Finucane; Rosemary Musonda; Sikhulile Moyo; Carolyn Wester; Erik van Widenfelt; Joseph Makhema; Stephen Lagakos; M Essex
Journal:  J Acquir Immune Defic Syndr       Date:  2009-01-01       Impact factor: 3.731

6.  Cellular HIV-1 DNA levels in drug sensitive strains are equivalent to those in drug resistant strains in newly-diagnosed patients in Europe.

Authors:  Victoria L Demetriou; David A M C van de Vijver; Ioanna Kousiappa; Claudia Balotta; Bonaventura Clotet; Zehava Grossman; Louise B Jørgensen; Snjezana Z Lepej; Itzchak Levy; Claus Nielsen; Dimitrios Paraskevis; Mario Poljak; Francois Roman; Lidia Ruiz; Jean-Claude Schmidt; Anne-Mieke Vandamme; Kristel Van Laethem; Jurgen Vercauteren; Leondios G Kostrikis
Journal:  PLoS One       Date:  2010-06-08       Impact factor: 3.240

7.  HIV DNA and cognition in a Thai longitudinal HAART initiation cohort: the SEARCH 001 Cohort Study.

Authors:  V G Valcour; B T Shiramizu; P Sithinamsuwan; S Nidhinandana; S Ratto-Kim; J Ananworanich; U Siangphoe; J H Kim; M de Souza; V Degruttola; R H Paul; C M Shikuma
Journal:  Neurology       Date:  2009-03-17       Impact factor: 9.910

8.  Dynamics of viral replication in blood and lymphoid tissues during SIVmac251 infection of macaques.

Authors:  Abdelkrim Mannioui; Olivier Bourry; Pierre Sellier; Benoit Delache; Patricia Brochard; Thibault Andrieu; Bruno Vaslin; Ingrid Karlsson; Pierre Roques; Roger Le Grand
Journal:  Retrovirology       Date:  2009-11-23       Impact factor: 4.602

9.  Supersensitive Viral Load Assay in Predicting CD4-Guided Treatment Failure.

Authors:  Simone Langford; Angele Gayet-Ageron; Chris Duncombe; Thidarat Jupimai; Apicha Mahanontharit; Sasisopin Kiertiburanakul; Warangkana Munsakul; Kiat Ruxrungtham; Bernard Hirschel; Jintanat Ananworanich
Journal:  Open Virol J       Date:  2008-10-16
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.